Answers are grounded in this paper and cite their sources.
Our current findings have shed light on the generation mechanism of pathogenic RANKL(+) effector B cells that would be an ideal therapeutic target for rheumatoid arthritis in the future.
No takes yet. Share an insight, caveat, or question.
Ota et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: